Distinct pathways of humoral and cellular immunity induced with the mucosal administration of a nanoemulsion adjuvant

Journal of Immunology

Volumn 192, Issue 6, 2014, Pages 2722-2733

  Bielinska, Anna U ^a   Makidon, Paul E ^a   Janczak, Katarzyna W ^a   Blanco, Luz P ^a   Swanson, Benjamin ^a   Smith, Douglas M ^a   Pham, Tiffany ^a   Szabo, Zsuzsanna ^a   Kukowska Latallo, Jolanta F ^a   Baker Jr , James R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR BETA1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYELOID DIFFERENTIATION FACTOR 88; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; W 80 5EC ADJUVANT;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG MECHANISM; FEMALE; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOMODULATION; INNATE IMMUNITY; MOUSE; MUCOSAL ADMINISTRATION; NANOEMULSION; NASAL IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TH1 CELL; TH17 CELL; UPREGULATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; CELL LINE; CELLS, CULTURED; DENDRITIC CELLS; EMULSIONS; FEMALE; HEK293 CELLS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTERLEUKIN-12; INTERLEUKIN-12 RECEPTOR BETA 1 SUBUNIT; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TRANSCRIPTOME;

EID: 84897510295     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301424     Document Type: Article

References (86)

1. Chen, W., G. B. Patel, H. Yan, and J. Zhang. 2010. Recent advances in the development of novel mucosal adjuvants and antigen delivery systems. Hum. Vaccin. 6: 706-714.
2. Belyakov, I. M., and J. D. Ahlers. 2009. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J. Immunol. 183: 6883-6892.
3. Lycke, N. 2012. Recent progress in mucosal vaccine development: potential and limitations. Nat. Rev. Immunol. 12: 592-605.
4. Getz, G. S. 2005. Thematic review series: the immune system and atherogenesis. Bridging the innate and adaptive immune systems. J. Lipid Res. 46: 619-622.
5. Barton, G. M., and R. Medzhitov. 2002. Control of adaptive immune responses by Toll-like receptors. Curr. Opin. Immunol. 14: 380-383.
6. Iwasaki, A., and R. Medzhitov. 2010. Regulation of adaptive immunity by the innate immune system. Science 327: 291-295.
7. Iwasaki, A., and R. Medzhitov. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5: 987-995.
8. Levitz, S. M., and D. T. Golenbock. 2012. Beyond empiricism: informing vaccine development through innate immunity research. Cell 148: 1284-1292.
9. Fraser, C. K., K. R. Diener, M. P. Brown, and J. D. Hayball. 2007. Improving vaccines by incorporating immunological coadjuvants. Expert Rev. Vaccines 6: 559-578.
10. Guy, B. 2007. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 5: 505-517.
11. van Duin, D., R. Medzhitov, and A. C. Shaw. 2006. Triggering TLR signaling in vaccination. Trends Immunol. 27: 49-55.
12. Mata-Haro, V., C. Cekic, M. Martin, P. M. Chilton, C. R. Casella, and T. C. Mitchell. 2007. The vaccine adjuvant monophosphoryl lipid A as a TRIFbiased agonist of TLR4. Science 316: 1628-1632.
13. Longhi, M. P., C. Trumpfheller, J. Idoyaga, M. Caskey, I. Matos, C. Kluger, A. M. Salazar, M. Colonna, and R. M. Steinman. 2009. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J. Exp. Med. 206: 1589-1602.
14. Gavin, A. L., K. Hoebe, B. Duong, T. Ota, C. Martin, B. Beutler, and D. Nemazee. 2006. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 314: 1936-1938.
15. Mestecky, J., M. W. Russell, and C. O. Elson. 2007. Perspectives on mucosal vaccines: is mucosal tolerance a barrier? J. Immunol. 179: 5633-5638.
16. Dunne, A., and L. A. O'Neill. 2003. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci. STKE 2003: re3.
17. Reis e Sousa, C. 2004. Activation of dendritic cells: translating innate into adaptive immunity. Curr. Opin. Immunol. 16: 21-25.
18. Greenwald, R. J., G. J. Freeman, and A. H. Sharpe. 2005. The B7 family revisited. Annu. Rev. Immunol. 23: 515-548.
19. Kapsenberg, M. L. 2003. Dendritic-cell control of pathogen-driven T-cell polarization. Nat. Rev. Immunol. 3: 984-993.
20. Feili-Hariri, M., D. H. Falkner, and P. A. Morel. 2005. Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy. J. Leukoc. Biol. 78: 656-664.
21. Sioud, M., and Y. Fløisand. 2007. TLR agonists induce the differentiation of human bone marrow CD34+ progenitors into CD11c+ CD80/86+ DC capable of inducing a Th1-type response. Eur. J. Immunol. 37: 2834-2846.
22. Sioud, M., Y. Fløisand, L. Forfang, and F. Lund-Johansen. 2006. Signaling through toll-like receptor 7/8 induces the differentiation of human bone marrow CD34+ progenitor cells along the myeloid lineage. J. Mol. Biol. 364: 945-954.
23. Li, H., S. Nookala, and F. Re. 2007. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J. Immunol. 178: 5271-5276.
24. Seubert, A., S. Calabro, L. Santini, B. Galli, A. Genovese, S. Valentini, S. Aprea, A. Colaprico, U. D'Oro, M. M. Giuliani, et al. 2011. Adjuvanticity of the oil-inwater emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc. Natl. Acad. Sci. USA 108: 11169-11174.
25. De Gregorio, E., E. Tritto, and R. Rappuoli. 2008. Alum adjuvanticity: unraveling a century old mystery. Eur. J. Immunol. 38: 2068-2071.
26. Franchi, L., and G. Núñez. 2008. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1β secretion but dispensable for adjuvant activity. Eur. J. Immunol. 38: 2085-2089.
27. Bielinska, A. U., M. Gerber, L. P. Blanco, P. E. Makidon, K. W. Janczak, B. Swanson, M. R. Beer, and J. R. Baker, Jr. 2010. Induction of Th17 cellular immunity with a novel nanoemulsion adjuvant. Crit. Rev. Immunol. 30: 189-199.
28. Hogenesch, H., A. Dunham, B. Hansen, K. Anderson, J. F. Maisonneuve, and S. L. Hem. 2011. Formulation of a killed whole cell pneumococcus vaccine - effect of aluminum adjuvants on the antibody and IL-17 response. J. Immune Based Ther. Vaccines 9: 5.
29. Garlapati, S. 2012. Do we know the Th1/Th2/Th17 determinants of vaccine response? Expert Rev. Vaccines 11: 1307-1310.
30. Curtis, M. M., and S. S. Way. 2009. Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunology 126: 177-185.
31. Bielinska, A. U., K. W. Janczak, J. J. Landers, D. M. Markovitz, D. C. Montefiori, and J. R. Baker, Jr. 2008. Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 24: 271-281.
32. Makidon, P. E., A. U. Bielinska, S. S. Nigavekar, K. W. Janczak, J. Knowlton, A. J. Scott, N. Mank, Z. Cao, S. Rathinavelu, M. R. Beer, et al. 2008. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS ONE 3: e2954.
33. Bielinska, A. U., A. A. Chepurnov, J. J. Landers, K. W. Janczak, T. S. Chepurnova, G. D. Luker, and J. R. Baker, Jr. 2008. A novel, killed-virus nasal vaccinia virus vaccine. Clin. Vaccine Immunol. 15: 348-358.
34. Bielinska, A. U., K. W. Janczak, J. J. Landers, P. Makidon, L. E. Sower, J. W. Peterson, and J. R. Baker, Jr. 2007. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect. Immun. 75: 4020-4029.
35. Myc, A., J. F. Kukowska-Latallo, A. U. Bielinska, P. Cao, P. P. Myc, K. Janczak, T. R. Sturm, M. S. Grabinski, J. J. Landers, K. S. Young, et al. 2003. Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion. Vaccine 21: 3801-3814.
36. Makidon, P. E., I. M. Belyakov, L. P. Blanco, K. W. Janczak, J. Landers, A. U. Bielinska, J. V. Groom, 2nd, and J. R. Baker, Jr. 2012. Nanoemulsion mucosal adjuvant uniquely activates cytokine production by nasal ciliated epithelium and induces dendritic cell trafficking. Eur. J. Immunol. 42: 2073-2086.
37. Myc, A., J. F. Kukowska-Latallo, D. M. Smith, C. Passmore, T. Pham, P. Wong, A. U. Bielinska, and J. R. J. Baker. 2013. Nanoemulsion nasal adjuvant W805EC induces dendritic cell engulfment of antigen-primed epithelial cells. Vaccine. 31: 1072-1079.
38. Dignam, J. D., R. M. Lebovitz, and R. G. Roeder. 1983. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11: 1475-1489.
39. Huang, W., B. T. Sherman, and R. A. Lempicki. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4: 44-57.
40. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
41. Kryczek, I., S. Wei, L. Zou, G. Zhu, P. Mottram, H. Xu, L. Chen, and W. Zou. 2006. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J. Immunol. 177: 40-44.
42. Leadbetter, E. A., I. R. Rifkin, A. M. Hohlbaum, B. C. Beaudette, M. J. Shlomchik, and A. Marshak-Rothstein. 2002. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416: 603-607.
43. Classen, D. C., J. M. Morningstar, and J. D. Shanley. 1987. Detection of antibody to murine cytomegalovirus by enzyme-linked immunosorbent and indirect immunofluorescence assays. J. Clin. Microbiol. 25: 600-604.
44. Frey, A., J. Di Canzio, and D. Zurakowski. 1998. A statistically defined endpoint titer determination method for immunoassays. J. Immunol. Methods 221: 35-41.
45. Duff, G. W., and E. Atkins. 1982. The inhibitory effect of polymyxin B on endotoxin-induced endogenous pyrogen production. J. Immunol. Methods 52: 333-340.
46. Cardoso, L. S., M. I. Araujo, A. M. Góes, L. G. Pacífico, R. R. Oliveira, and S. C. Oliveira. 2007. Polymyxin B as inhibitor of LPS contamination of Schistosoma mansoni recombinant proteins in human cytokine analysis. Microb. Cell Fact. 6: 1.
47. Park, B. S., D. H. Song, H. M. Kim, B.-S. Choi, H. Lee, and J.-O. Lee. 2009. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458: 1191-1195.
48. Münz, C., R. M. Steinman, and S.-i. Fujii. 2005. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J. Exp. Med. 202: 203-207.
49. Gately, M. K., L. M. Renzetti, J. Magram, A. S. Stern, L. Adorini, U. Gubler, and D. H. Presky. 1998. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 16: 495-521.
50. Lindblad, E. B. 2004. Aluminium compounds for use in vaccines. Immunol. Cell Biol. 82: 497-505.
51. O'Hagan, D. T., M. Singh, C. Dong, M. Ugozzoli, K. Berger, E. Glazer, M. Selby, M. Wininger, P. Ng, K. Crawford, et al. 2004. Cationic microparticles are a potent delivery system for a HCV DNA vaccine. Vaccine 23: 672-680.
52. O'Hagan, D. T., and E. De Gregorio. 2009. The path to a successful vaccine adjuvant-'the long and winding road'. Drug Discov. Today 14: 541-551.
53. O'Hagan, D. T., and M. Singh. 2007. MF59: A Safe and Potent Oil-in-Water Emulsion Adjuvant. In Vaccine Adjuvants and Delivery Systems. M. Singh, ed. John Wiley & Sons, Hoboken, NJ, p. 115-129.
54. Makidon, P. E., S. S. Nigavekar, A. U. Bielinska, N. Mank, A. M. Shetty, J. Suman, J. Knowlton, A. Myc, T. Rook, and J. R. Baker. 2010. Characterization of stability and nasal delivery systems for immunization with nanoemulsionbased vaccines. J. Aerosol Med. Pulm. Drug Deliv. 23: 77-89.
55. Pahl, H. L. 1999. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18: 6853-6866.
56. Gilmore, T. D. 1999. The Rel/NF-kappaB signal transduction pathway: introduction. Oncogene 18: 6842-6844.
57. Solt, L. A., and M. J. May. 2008. The IkappaB kinase complex: master regulator of NF-kappaB signaling. Immunol. Res. 42: 3-18.
58. Simons, K., and D. Toomre. 2000. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 1: 31-39.
59. Kabouridis, P. S. 2006. Lipid rafts in T cell receptor signalling. Mol. Membr. Biol. 23: 49-57.
60. Flach, T. L., G. Ng, A. Hari, M. D. Desrosiers, P. Zhang, S. M. Ward, M. E. Seamone, A. Vilaysane, A. D. Mucsi, Y. Fong, et al. 2011. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat. Med. 17: 479-487.
61. Lonez, C., M. F. Lensink, M. Vandenbranden, and J.M. Ruysschaert. 2009. Cationic lipids activate cellular cascades. Which receptors are involved? Biochim. Biophys. Acta 1790: 425-430.
62. Loscher, C. E., E. Draper, O. Leavy, D. Kelleher, K. H. Mills, and H. M. Roche. 2005. Conjugated linoleic acid suppresses NF-kappa B activation and IL-12 production in dendritic cells through ERK-mediated IL-10 induction. J. Immunol. 175: 4990-4998.
63. Lee, J. Y., J. Ye, Z. Gao, H. S. Youn, W. H. Lee, L. Zhao, N. Sizemore, and D. H. Hwang. 2003. Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J. Biol. Chem. 278: 37041-37051.
64. Conwell, C. C., F. Liu, and L. Huang. 2008. Several serum proteins significantly decrease inflammatory response to lipid-based non-viral vectors. Mol. Ther. 16: 370-377.
65. Yang, Y.-W., C.-A. Wu, and W. J. Morrow. 2004. Cell death induced by vaccine adjuvants containing surfactants. Vaccine 22: 1524-1536.
66. Pasare, C., and R. Medzhitov. 2005. Control of B-cell responses by Toll-like receptors. Nature 438: 364-368.
67. Nemazee, D., A. Gavin, K. Hoebe, and B. Beutler. 2006. Immunology: Toll-like receptors and antibody responses. Nature 441: E4; discussion E4.
68. Abdollahi-Roodsaz, S., L. A. Joosten, M. I. Koenders, I. Devesa, M. F. Roelofs, T. R. Radstake, M. Heuvelmans-Jacobs, S. Akira, M. J. Nicklin, F. Ribeiro-Dias, and W. B. van den Berg. 2008. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J. Clin. Invest. 118: 205-216.
69. Sabroe, I., L. R. Prince, E. C. Jones, M. J. Horsburgh, S. J. Foster, S. N. Vogel, S. K. Dower, and M. K. B. Whyte. 2003. Selective roles for Toll-like receptor (TLR)2 and TLR4 in the regulation of neutrophil activation and life span. J. Immunol. 170: 5268-5275.
70. Querec, T., S. Bennouna, S. Alkan, Y. Laouar, K. Gorden, R. Flavell, S. Akira, R. Ahmed, and B. Pulendran. 2006. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203: 413-424.
71. Chen, L., L. Lei, X. Chang, Z. Li, C. Lu, X. Zhang, Y. Wu, I.-T. Yeh, and G. Zhong. 2010. Mice deficient in MyD88 develop a Th2-dominant response and severe pathology in the upper genital tract following Chlamydia muridarum infection. J. Immunol. 184: 2602-2610.
72. Su, S. B., P. B. Silver, R. S. Grajewski, R. K. Agarwal, J. Tang, C.-C. Chan, and R. R. Caspi. 2005. Essential role of the MyD88 pathway, but nonessential roles of TLRs 2, 4, and 9, in the adjuvant effect promoting Th1-mediated autoimmunity. J. Immunol. 175: 6303-6310.
73. Fransen, F., R. M. Stenger, M. C. Poelen, H. H. van Dijken, B. Kuipers, C. J. Boog, J. P. van Putten, C. A. van Els, and P. van der Ley. 2010. Differential effect of TLR2 and TLR4 on the immune response after immunization with a vaccine against Neisseria meningitidis or Bordetella pertussis. PLoS ONE 5: e15692.
74. Del Vecchio, M., E. Bajetta, S. Canova, M. T. Lotze, A. Wesa, G. Parmiani, and A. Anichini. 2007. Interleukin-12: biological properties and clinical application. Clin. Cancer Res. 13: 4677-4685.
75. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13: 251-276.
76. Magram, J., S. E. Connaughton, R. R. Warrier, D. M. Carvajal, C. Y. Wu, J. Ferrante, C. Stewart, U. Sarmiento, D. A. Faherty, and M. K. Gately. 1996. IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity 4: 471-481.
77. Chang, J., P. R. Burkett, C. M. Borges, V. K. Kuchroo, L. A. Turka, and C.-H. Chang. 2013. MyD88 is essential to sustain mTOR activation necessary to promote T helper 17 cell proliferation by linking IL-1 and IL-23 signaling. Proc. Natl. Acad. Sci. USA 110: 2270-2275.
78. Iwakura, Y., and H. Ishigame. 2006. The IL-23/IL-17 axis in inflammation. J. Clin. Invest. 116: 1218-1222.
79. John, B., D. Rajagopal, A. Pashine, S. Rath, A. George, and V. Bal. 2002. Role of IL-12-independent and IL-12-dependent pathways in regulating generation of the IFN-gamma component of T cell responses to Salmonella typhimurium. J. Immunol. 169: 2545-2552.
80. Mori, A., E. Oleszycka, F. A. Sharp, M. Coleman, Y. Ozasa, M. Singh, D. T. O'Hagan, L. Tajber, O. I. Corrigan, E. A. McNeela, and E. C. Lavelle. 2012. The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses. Eur. J. Immunol. 42: 2709-2719.
81. Hogenesch, H. 2013. Mechanism of immunopotentiation and safety of aluminum adjuvants. Front. Immunol. 3: 406.
82. Odobasic, D., A. R. Kitching, P. G. Tipping, and S. R. Holdsworth. 2005. CD80 and CD86 costimulatory molecules regulate crescentic glomerulonephritis by different mechanisms. Kidney Int. 68: 584-594.
83. Schweitzer, A. N., and A. H. Sharpe. 1998. Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production. J. Immunol. 161: 2762-2771.
84. Carreno, B. M., and M. Collins. 2002. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20: 29-53.
85. Borriello, F., M. P. Sethna, S. D. Boyd, A. N. Schweitzer, E. A. Tivol, D. Jacoby, T. B. Strom, E. M. Simpson, G. J. Freeman, and A. H. Sharpe. 1997. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity 6: 303-313.
86. Zhang, P., J. P. Lewis, S. M. Michalek, and J. Katz. 2007. Role of CD80 and CD86 in host immune responses to the recombinant hemagglutinin domain of Porphyromonas gingivalis gingipain and in the adjuvanticity of cholera toxin B and monophosphoryl lipid A. Vaccine 25: 6201-6210.